Detalles de la búsqueda
1.
Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study.
Clin Infect Dis
; 71(10): e594-e603, 2020 12 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-32201897
2.
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans.
J Antimicrob Chemother
; 74(2): 442-452, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30376079
3.
Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
J Infect Dis
; 218(5): 748-756, 2018 07 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29684148
4.
A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations.
Pharm Res
; 34(2): 333-351, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27864744
5.
CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
Paediatr Drugs
; 26(4): 411-427, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649595
6.
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.
PLoS One
; 18(7): e0288271, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37467213
7.
A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.
Clin Microbiol Infect
; 29(10): 1320-1327, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37422079
8.
Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor.
Adv Ther
; 37(1): 578-591, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31832988
9.
A comparison of RSV and influenza in vitro kinetic parameters reveals differences in infecting time.
PLoS One
; 13(2): e0192645, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29420667
10.
In vitro and in silico analysis of the effects of D2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations.
Br J Pharmacol
; 175(21): 4121-4136, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30051456
11.
Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach.
Eur J Pharm Sci
; 112: 168-179, 2018 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29133240
12.
A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores.
Eur J Pharm Sci
; 109S: S154-S160, 2017 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28606804
13.
Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients.
Eur J Drug Metab Pharmacokinet
; 42(5): 801-814, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28078530
14.
Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
Clin Pharmacokinet
; 56(11): 1331-1342, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28238203
15.
Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?
Pharmacol Res Perspect
; 5(6)2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29226628
16.
Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model.
CPT Pharmacometrics Syst Pharmacol
; 6(11): 765-777, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28891201
17.
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.
Nat Commun
; 8(1): 167, 2017 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28761099
18.
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers.
Br J Pharmacol
; 148(4): 396-404, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16682968
19.
Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain.
Clin Drug Investig
; 36(3): 213-23, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26798023
20.
A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.
Eur J Pharmacol
; 789: 202-214, 2016 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27395799